JPMorgan Chase & Co. lifted its holdings in Retrophin, Inc. (NASDAQ:RTRX) by 4.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 137,526 shares of the biopharmaceutical company’s stock after purchasing an additional 5,674 shares during the period. JPMorgan Chase & Co. owned about 0.36% of Retrophin worth $2,667,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in RTRX. Nationwide Fund Advisors lifted its position in shares of Retrophin by 129.9% in the 1st quarter. Nationwide Fund Advisors now owns 51,841 shares of the biopharmaceutical company’s stock worth $957,000 after purchasing an additional 29,290 shares during the period. Wells Fargo & Company MN raised its stake in shares of Retrophin by 12.8% during the 1st quarter. Wells Fargo & Company MN now owns 50,785 shares of the biopharmaceutical company’s stock worth $938,000 after acquiring an additional 5,763 shares in the last quarter. American International Group Inc. raised its stake in shares of Retrophin by 7.1% during the 1st quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after acquiring an additional 1,475 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Retrophin during the 1st quarter worth approximately $219,000. Finally, FMR LLC raised its stake in shares of Retrophin by 24.8% during the 1st quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock worth $36,161,000 after acquiring an additional 389,714 shares in the last quarter.
Several research analysts recently commented on the stock. BMO Capital Markets reiterated a “buy” rating and set a $44.00 price objective on shares of Retrophin in a research note on Friday, October 6th. BidaskClub upgraded shares of Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Finally, ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $36.00.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The business had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The business’s revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.07 earnings per share.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the transaction, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at approximately $306,495. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.41% of the company’s stock.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).
What are top analysts saying about Retrophin Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin Inc. and related companies.